Cantor Fitzgerald Estimates uniQure FY2025 Earnings

uniQure (NASDAQ:QURE) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of uniQure in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the biotechnology company will post earnings of ($1.87) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $58.00 price target on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.74) per share.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million.

Several other research analysts also recently issued reports on QURE. Stifel Nicolaus upped their price objective on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, December 16th. Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price target on shares of uniQure in a research note on Tuesday. Mizuho raised their price objective on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th. Finally, Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and boosted their target price for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.38.

uniQure Stock Up 2.5 %

NASDAQ QURE opened at $15.29 on Thursday. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock’s 50 day moving average is $12.39 and its two-hundred day moving average is $8.56.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.74% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. abrdn plc raised its stake in uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after acquiring an additional 1,528,581 shares in the last quarter. Franklin Resources Inc. acquired a new position in uniQure during the 3rd quarter worth approximately $7,360,000. Point72 Asset Management L.P. lifted its stake in uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after purchasing an additional 752,889 shares during the last quarter. Privium Fund Management B.V. grew its stake in shares of uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after buying an additional 104,500 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after buying an additional 6,362 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.